Celldex Therapeutics, Inc. (CLDX)
 NASDAQ: CLDX · Real-Time Price · USD
 26.00
 +0.01 (0.04%)
  At close: Oct 30, 2025, 4:00 PM EDT
26.06
 +0.06 (0.23%)
  After-hours: Oct 30, 2025, 6:28 PM EDT
Celldex Therapeutics Employees
Celldex Therapeutics had 186 employees as of December 31, 2024. The number of employees increased by 26 or 16.25% compared to the previous year.
Employees 
 186
Change (1Y) 
 26
Growth (1Y) 
 16.25%
Revenue / Employee 
 $31,129
Profits / Employee 
 -$1,073,167
Market Cap 
1.73B
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 186 | 26 | 16.25% | 
| Dec 31, 2023 | 160 | 12 | 8.11% | 
| Dec 31, 2022 | 148 | 14 | 10.45% | 
| Dec 31, 2021 | 134 | 9 | 7.20% | 
| Dec 31, 2020 | 125 | -5 | -3.85% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
CLDX News
- 6 weeks ago - Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 - GlobeNewsWire
- 7 weeks ago - Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track - Seeking Alpha
- 2 months ago - Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short - Benzinga
- 2 months ago - Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) - GlobeNewsWire
- 3 months ago - Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewsWire